SPOTLIGHT: Sepracor touts data


Sepracor says its experimental therapy for seasonal allergic rhinitis hit its primary and secondary endpoints in a mid-stage trial. Omnaris "demonstrated a statistically significant reduction in 24-hour total nasal symptom scores versus placebo." Release | Report

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.